Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Niti Aayog meets Top...

    Niti Aayog meets Top pharma execs to find ways to mitigate coronavirus impact; DoP seeks export ban on 12 APIs

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-21T11:58:44+05:30  |  Updated On 21 Feb 2020 11:58 AM IST
    Niti Aayog meets Top pharma execs to find ways to mitigate coronavirus impact; DoP seeks export ban on 12 APIs

    The meeting was attended by Biocon's Kiran Mazumdar Shaw, Zydus' Pankaj Patel and Dr Reddy's Laboratories' Satish Reddy and other top pharma execs

    New Delhi: Government think-tank Niti Aayog along with top executives of pharma industry and senior officials on Wednesday discussed ways to boost domestic manufacturing of Active Pharmaceutical Ingredients (APIs), amid concerns over supply disruption from China due to the coronavirus outbreak.

    The meeting, chaired by Niti Aayog CEO Amitabh Kant, came a day after Finance Minister Nirmala Sitharaman said the government would soon announce measures to deal with the impact of the coronavirus outbreak on the domestic industry.

    China, which is battling the coronavirus epidemic, is a major supplier of bulk drugs and drug intermediaries to the Indian market. There are concerns about supply disruptions and a possible rise in medicine prices.

    Sources said a host of measures were discussed at the meeting on Wednesday to boost domestic manufacturing of APIs and reduce dependence on their imports from China.

    The meeting was attended by Pharmaceuticals Department Secretary P D Vaghela, Biocon's Kiran Mazumdar Shaw, Zydus' Pankaj Patel and Dr Reddy's Laboratories' Satish Reddy.

    Senior executives from Sun Pharma, Aurobindo, Jubilant Life Sciences, Cipla, Mylan, Alembic and Themis also participated in the meeting. Presidents of Bulk Drug Manufacturers Association, Indian Drug Manufacturers Association and Indian Pharmaceutical Alliance were also present.

    "Fruitful, constructive & positive meeting with captains of industry in pharmaceutical sector to discuss the options for domestic manufacturing of critical APIs on which India is import dependent. Consensus arrived at on a range of policy measures for creating ecosystem in India," Kant said in a tweet after the meeting.

    He also said the government would take all necessary steps to support the industry in its endeavours.

    China accounted for 67.56 per cent of total imports of bulk drugs and drug intermediates at USD 2,405.42 million to India in 2018-19.

    Separately, the Department of Pharmaceuticals (DoP) has asked the Directorate General of Foreign Trade (DGFT) to issue orders restricting export of 12 APIs and formulations.

    Read Also: Primary healthcare can play key role in combating outbreaks like coronavirus: Biocon Chief Kiran Mazumdar-Shaw

    The DoP has already constituted a high-level panel to assess the impact of the outbreak of the deadly virus in China on the supply of APIs to India.

    Official sources had said that Indian drugmakers have told the high-level committee that they currently have stocks for the next two-three months.

    There has been no supply from the neighbouring country for the past 20-25 days, mainly due to Chinese New Year holidays, sources had said.

    According to an official statement issued on Wednesday after the meeting, Kant exhorted the industry to become internationally competitive and go for a global scale of operations.

    The DoP shared its vision and recent efforts in promoting bulk drug parks in the country, the statement said.

    "Issues related to environmental clearances were discussed in detail and industry was promised fast approvals," it added.

    On Tuesday, Zydus Group Chairman Pankaj Patel said prices of key pharmaceutical ingredients could rise if the coronavirus situation in China does not improve soon.

    Describing pharmaceutical, chemical and solar equipment sectors as the worst affected, Sitharaman on Tuesday said said disruptions are visible in these due to delay in shipment.

    She had met representatives from various sectors on Tuesday.

    PharmaNiti Aayogbioconkiran mazumdar shawPankaj R Patelsatish reddy
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok